# US 10,308,939 B2 · Use of an miRNA to reduce proliferation of a cancer cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,939 B2
- Document ID: US10308939B2
- Status: Granted
- Kind: B2
- Application number: 15/880,032
- Filed: 2018-01-25
- Published: 2018-06-07
- Granted: 2019-06-04
- Earliest claimed: 2014-07-21
- Assignees: Board of Supervisors of Louisiana State University
- Applicants: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Inventors: Francesca Peruzzi; Duane Jeansonne
- Web page: https://patentgrep.com/patent/US10308939B2

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for decreasing at least one of the proliferation and the migration of a cancer cell comprising contacting a cancer cell with an effective amount of a pharmaceutically acceptable composition comprising a microRNA (miRNA) having a nucleotide sequence having at least 80% sequence similarity to the nucleotide sequence of miR-3189-3p derived from the miR-3189 mitron of the Growth Differentiation Factor 15 (GDF15) gene. The methods and compositions are advantageous for inhibiting proliferation and migration of, but not limited to, glioblastoma cells, melanoma cells, and breast cancer cells.

## Claims

### Claim 1

A method for decreasing at least one of the proliferation and the migration of a glial tumor cell, comprising contacting the cancer cell with a pharmaceutically acceptable composition comprising a microRNA (miRNA) having the nucleotide sequence SEQ ID NO: 2, thereby decreasing at least one of the proliferation and migration of the cancer cell as compared to a control.

### Claim 2 (depends on 1)

The method of claim 1, wherein the glial tumor cell is an astrocytoma tumor cell, an ependymal tumor cell, a glioblastoma multiforme tumor cell, or a primitive neuroectodermal tumor cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein the glioblastoma multiforme is located in the brain or the spinal cord of the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the miRNA reduces the expression of at least one of p63RoGEF and SF3B2 splicing factor in the cancer cell, or modulates the effect of MYC in the cancer cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer cell is an isolated cancer cell, a cultured cell, a cell in a tissue of an animal or human patient, or progeny thereof.

### Claim 6

A method for treating a cancer, wherein the cancer is a glial tumor, the method comprising administering to an animal or human subject in need thereof an effective amount of a pharmaceutically acceptable composition consisting essentially of a microRNA (miRNA) having the nucleotide sequence SEQ ID NO: 2, thereby decreasing at least one of the proliferation and migration of the cancer cell as compared to a control.

### Claim 7 (depends on 6)

The method of claim 6, wherein the glial tumor cell is an astrocytoma tumor cell, an ependymal tumor cell, a glioblastoma multiforme tumor cell, or a primitive neuroectodermal tumor cell.

### Claim 8 (depends on 6)

The method of claim 6, wherein the glioblastoma multiforme is located in the brain or the spinal cord of the subject.

### Claim 9 (depends on 6)

The method of claim 6, wherein the miRNA reduces the expression of at least one of p63RoGEF and SF3B2 splicing factor in the cancer cell, or modulates the effect of MYC in the cancer cell.

### Claim 10 (depends on 6)

The method of claim 6, wherein the pharmaceutically acceptable composition is administered to the animal or human subject intravenously, subcutaneously, or intratumorally.

### Claim 11 (depends on 6)

The method of claim 6, wherein the pharmaceutically acceptable composition is formulated to deliver the miRNA across the blood-brain barrier or to deliver the miRNA as a nucleic acid expression product to the cells of the cancer.